The RDHL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RDHL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The RDHL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View RDHL Detailed Price Forecast - CNN Money||View RDHL Detailed Summary - Google Finance|
|View RDHL Detailed Summary - Yahoo! Finance||View RDHL Stock Research & Analysis - Zacks.com|
|View RDHL Trends & Analysis - Trade-Ideas||View RDHL Major Holders - Barrons|
|View RDHL Call Transcripts - NASDAQ||View RDHL Breaking News & Analysis - Seeking Alpha|
|View RDHL Annual Report - CompanySpotlight.com||View RDHL OTC Short Report - OTCShortReport.com|
|View RDHL Fundamentals - TradeKing||View RDHL SEC Filings - Bar Chart|
|View Historical Prices for RDHL - The WSJ||View Performance/Total Return for RDHL - Morningstar|
|View the Analyst Estimates for RDHL - MarketWatch||View the Earnings History for RDHL - CNBC|
|View the RDHL Earnings - StockMarketWatch||View RDHL Buy or Sell Recommendations - MacroAxis|
|View the RDHL Bullish Patterns - American Bulls||View RDHL Short Pain Metrics - ShortPainBot.com|
|View RDHL Stock Mentions - StockTwits||View RDHL Stock Mentions - PennyStockTweets|
|View RDHL Stock Mentions - Twitter||View RDHL Investment Forum News - Investor Hub|
|View RDHL Stock Mentions - Yahoo! Message Board||View RDHL Stock Mentions - Seeking Alpha|
|View Insider Transactions for RDHL - SECform4.com||View Insider Transactions for RDHL - Insider Cow|
|View RDHL Major Holdings Summary - CNBC||View Insider Disclosure for RDHL - OTC Markets|
|View Insider Transactions for RDHL - Yahoo! Finance||View Institutional Holdings for RDHL - NASDAQ|
|View RDHL Stock Insight & Charts - FinViz.com||View RDHL Investment Charts - StockCharts.com|
|View RDHL Stock Overview & Charts - BarChart||View RDHL User Generated Charts - Trading View|
RedHill closes $20M public offering to prep commercialization of new drug
Posted on Wednesday December 12, 2018
RedHill Biopharma just closed on a $20 million public offering to fund the commercial launch of its drug, Talicia – which means expansion of the company's Raleigh team.
RedHill Biopharma Announces Closing of $20 Million Underwritten Offering
Posted on Tuesday December 11, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the closing of its previously announced underwritten public offering for a total number of 2,857,143 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at a public offering price of $7.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 428,571 additional ADSs at the public offering price.
RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering
Posted on Thursday December 06, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 06, 2018 -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty.
RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
Posted on Tuesday December 04, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it intends to offer its American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs offered to the public. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund preparations for TALICIA® (H. pylori) commercial launch and commercialization activities, clinical development programs, including initiation of a pivotal Phase III study with RHB-204 for NTM, preparations for a second Phase III study with RHB-104 for Crohn’s disease and for acquisitions and general corporate purposes.